Trodelvy is now FDA-approved for first-line treatment of advanced TNBC, significantly improving PFS in phase 3 trials.
Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 ...
Big White Ski Resort is opening for its summer season on July 1, with a Canada Day present for mountain bikers.
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall ...
From a spectacular rally that stunned Ben Johns to a growing debate over tactics, intimidation and sportsmanship, the body ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...
Sweden have made three changes to their starting line-up ahead of their final Group F match, needing a point against Japan to ...
(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...
Newsable Asianet News on MSN
PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug
In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival ...
In 2025, the Food and Drug Administration (FDA) granted full approval to Zepzelca, in combination with Roche Holding 's ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results